Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 3/20 | 0.54 |
| ▸ | TYK2 | P29597 | 1/20 | 0.43 |
| ▸ | CHUK | O15111 | 1/20 | 0.43 |
| ▸ | EGFR | P00533 | 4/20 | 0.43 |
| ▸ | MAPT | P10636 | 4/20 | 0.43 |
| ▸ | BCL6 | P41182 | 3/20 | 0.41 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.38 |
| ▸ | PYGM | P11217 | 1/20 | 0.38 |
| ▸ | BTK | Q06187 | 1/20 | 0.37 |
| ▸ | THRB | P10828 | 1/20 | 0.36 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12391860 | 0.70 | KDR (1.00) | KDRCHUKEGFRMAPTBCL6 | |
| SCHEMBL2479595 | 0.69 | HTR2C (0.52) | KDRCHUKEGFRMAPTBCL6 | |
| SCHEMBL9643328 | 0.65 | MAPT (0.58) | KDRCHUKEGFRMAPTBCL6 | |
| SCHEMBL4969317 | 0.64 | NPY5R (0.66) | EGFRROCK1MAPK14 | |
| SCHEMBL30186735 | 0.62 | ADORA2A (0.59) | KDREGFRMAPTBCL6 | |
| SCHEMBL30162764 | 0.62 | CHUK (0.50) | KDRCHUKEGFRMAPTBCL6 | |
| SCHEMBL28229106 | 0.62 | MAPT (0.47) | KDRCHUKEGFRMAPTBCL6 | |
| SCHEMBL5355400 | 0.62 | CHUK (0.50) | KDRCHUKEGFRMAPTBCL6 | |
| SCHEMBL8834089 | 0.61 | KDR (0.46) | KDRTYK2EGFRMAPTROCK1 | |
| SCHEMBL5355413 | 0.61 | BRAF (0.73) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2155751-A1 | PYRROLOPYRIMIDIN-7-ONE DERIVATIVES AND THEIR USE AS PHARMACEUTICALS | AstraZeneca AB (SE) | 2010-02-24 | — | — | EP | claimed |
| US-20090099195-A1 | Therapeutic Compounds 570 | ASTRAZENECA AB (SE) | 2009-04-16 | — | — | US | claimed |
| WO-2008136756-A1 | PYRROLOPYRIMIDIN-7-ONE DERIVATIVES AND THEIR USE AS PHARMACEUTICALS | ASTRAZENECA AB (SE) | 2008-11-13 | — | — | WO | claimed |
| EP-2155751-A1 | PYRROLOPYRIMIDIN-7-ONE DERIVATIVES AND THEIR USE AS PHARMACEUTICALS | AstraZeneca AB (SE) | 2010-02-24 | — | — | EP | disclosed |
| WO-2008136756-A1 | PYRROLOPYRIMIDIN-7-ONE DERIVATIVES AND THEIR USE AS PHARMACEUTICALS | ASTRAZENECA AB (SE) | 2008-11-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090099195-A1 | Therapeutic Compounds 570 | OPRL1, OPRK1, OPRM1 | KDR 2439/4885TYK2 3907/4885CHUK 1432/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.